VIT Stock Overview
Engages in the sale and distribution of medicinal cannabis products in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vitura Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.078 |
| 52 Week High | AU$0.28 |
| 52 Week Low | AU$0.068 |
| Beta | 0.056 |
| 1 Month Change | -22.00% |
| 3 Month Change | 6.85% |
| 1 Year Change | -69.41% |
| 3 Year Change | -61.00% |
| 5 Year Change | -63.72% |
| Change since IPO | -77.06% |
Recent News & Updates
Recent updates
There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise
Oct 17
Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Oct 13Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture
Sep 07Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings
Aug 12Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Aug 12The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Feb 25Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)
Dec 13Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet
Nov 21Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?
Nov 01Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Jul 18Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%
Sep 12If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity
Sep 05Shareholder Returns
| VIT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 4.0% | 1.9% | 2.4% |
| 1Y | -69.4% | -10.0% | 7.7% |
Return vs Industry: VIT underperformed the Australian Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: VIT underperformed the Australian Market which returned 7.7% over the past year.
Price Volatility
| VIT volatility | |
|---|---|
| VIT Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: VIT has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: VIT's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Geoff Cockerill | vitura.com.au |
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a medicinal cannabis clinic that offers telehealth consultations.
Vitura Health Limited Fundamentals Summary
| VIT fundamental statistics | |
|---|---|
| Market cap | AU$45.37m |
| Earnings (TTM) | AU$3.51m |
| Revenue (TTM) | AU$123.87m |
12.9x
P/E Ratio0.4x
P/S RatioIs VIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIT income statement (TTM) | |
|---|---|
| Revenue | AU$123.87m |
| Cost of Revenue | AU$89.65m |
| Gross Profit | AU$34.22m |
| Other Expenses | AU$30.71m |
| Earnings | AU$3.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.006 |
| Gross Margin | 27.63% |
| Net Profit Margin | 2.84% |
| Debt/Equity Ratio | 13.8% |
How did VIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 07:30 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vitura Health Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |